Xermelo for Carcinoid Syndrome Diarrhea Now Available In Pharmacies

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

The FDA has recently approved Xermelo (telotristat ethyl), a new prescription medication for adults with carcinoid syndrome diarrhea. Xermelo is the first and only oral treatment for carcinoid syndrome diarrhea – so this is exciting news for those who suffer from the signs and symptoms of carcinoid syndrome.

Carcinoid syndrome is caused by a rare tumor that can lead to symptoms like skin lesions, difficulty breathing, and diarrhea.

How should I take Xermelo?

Xermelo must be used in conjunction with a somatostatin analog (SSA) like Sandostatin (octreotide) or Somatuline Depot (lanreotide). It is now available in pharmacies as a tablet in a strength of 250 mg. Patients should take one 250 mg tablet by mouth, three times daily with food.

Note that Xermelo is a specialty medication. This means that you must get Xermelo through a specialty pharmacy. Your doctor will fill out an enrollment form for you, which will be sent directly to a specialty pharmacy. Once the pharmacy receives the enrollment form from your doctor, you will be contacted by the LexCares program within 24 hours to set up delivery. Xermelo’s manufacturer, Lexicon Pharmaceuticals, created the LexCares program to get patients their medication without hassle.

What are the common side effects associated with Xermelo?

The most common side effects include a headache, nausea, increased liver enzymes, depression, swelling, gas, decreased appetite, and fever.

For more information about Xermelo, see the FDA’s press announcement here, or check out Xermelo’s website here.

Drugs featured in this story

Filed under